Literature DB >> 16234811

Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice.

Marta Paterlini1, Stanislav S Zakharenko, Wen-Sung Lai, Jie Qin, Hui Zhang, Jun Mukai, Koen G C Westphal, Berend Olivier, David Sulzer, Paul Pavlidis, Steven A Siegelbaum, Maria Karayiorgou, Joseph A Gogos.   

Abstract

Microdeletions of 22q11.2 represent one of the highest known genetic risk factors for schizophrenia. It is likely that more than one gene contributes to the marked risk associated with this locus. Two of the candidate risk genes encode the enzymes proline dehydrogenase (PRODH) and catechol-O-methyltransferase (COMT), which modulate the levels of a putative neuromodulator (L-proline) and the neurotransmitter dopamine, respectively. Mice that model the state of PRODH deficiency observed in humans with schizophrenia show increased neurotransmitter release at glutamatergic synapses as well as deficits in associative learning and response to psychomimetic drugs. Transcriptional profiling and pharmacological manipulations identified a transcriptional and behavioral interaction between the Prodh and Comt genes that is likely to represent a homeostatic response to enhanced dopaminergic signaling in the frontal cortex. This interaction modulates a number of schizophrenia-related phenotypes, providing a framework for understanding the high disease risk associated with this locus, the expression of the phenotype, or both.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16234811     DOI: 10.1038/nn1562

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  109 in total

1.  Long-term proline exposure alters nucleotide catabolism and ectonucleotidase gene expression in zebrafish brain.

Authors:  Luiz Eduardo Baggio Savio; Fernanda Cenci Vuaden; Denis B Rosemberg; Maurício R Bogo; Carla Denise Bonan; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2012-06-07       Impact factor: 3.584

2.  Evidence for altered hippocampal function in a mouse model of the human 22q11.2 microdeletion.

Authors:  Liam J Drew; Kimberly L Stark; Karine Fénelon; Maria Karayiorgou; Amy B Macdermott; Joseph A Gogos
Journal:  Mol Cell Neurosci       Date:  2011-05-24       Impact factor: 4.314

Review 3.  Small RNA-mediated gene regulation in neurodevelopmental disorders.

Authors:  Abrar Qurashi; Peng Jin
Journal:  Curr Psychiatry Rep       Date:  2010-04       Impact factor: 5.285

Review 4.  Genome-wide approaches to schizophrenia.

Authors:  Jubao Duan; Alan R Sanders; Pablo V Gejman
Journal:  Brain Res Bull       Date:  2010-04-28       Impact factor: 4.077

Review 5.  The 22q11.2 microdeletion: fifteen years of insights into the genetic and neural complexity of psychiatric disorders.

Authors:  Liam J Drew; Gregg W Crabtree; Sander Markx; Kimberly L Stark; Florence Chaverneff; Bin Xu; Jun Mukai; Karine Fenelon; Pei-Ken Hsu; Joseph A Gogos; Maria Karayiorgou
Journal:  Int J Dev Neurosci       Date:  2010-10-08       Impact factor: 2.457

Review 6.  The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan.

Authors:  Rachel K Jonas; Caroline A Montojo; Carrie E Bearden
Journal:  Biol Psychiatry       Date:  2013-08-28       Impact factor: 13.382

Review 7.  Converging levels of analysis on a genomic hotspot for psychosis: insights from 22q11.2 deletion syndrome.

Authors:  Matthew J Schreiner; Maria T Lazaro; Maria Jalbrzikowski; Carrie E Bearden
Journal:  Neuropharmacology       Date:  2012-10-23       Impact factor: 5.250

Review 8.  Electrophysiological endophenotypes in rodent models of schizophrenia and psychosis.

Authors:  Andrew M Rosen; Timothy Spellman; Joshua A Gordon
Journal:  Biol Psychiatry       Date:  2015-03-27       Impact factor: 13.382

9.  A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition.

Authors:  Mirna Kvajo; Heather McKellar; P Alexander Arguello; Liam J Drew; Holly Moore; Amy B MacDermott; Maria Karayiorgou; Joseph A Gogos
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-05       Impact factor: 11.205

Review 10.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.